Navigation Links
IDM Pharma Provides Update on Mifamurtide (L-MTP-PE) Regulatory Status Following June Meeting of European Committee for Medicinal Products for Human Use (CHMP)
Date:7/1/2008

- Company continues to anticipate CHMP opinion in the third quarter; L-MTP-PE on track for final European Commission decision in the fourth

quarter

IRVINE, Calif., July 1 /PRNewswire-FirstCall/ -- IDM Pharma, Inc. (Nasdaq: IDMI) today announced that the CHMP, following their June 2008 meeting, has requested additional data analyses from the Phase 3 L-MTP-PE trial (INT-0133). The Company expects to complete the additional data analyses, respond to questions received from the CHMP regarding the recent inspection of the Children's Oncology Group (COG), and address the remaining chemistry, manufacturing and control (CMC) issues by the end of August according to the current CHMP timeline. It is anticipated that the CHMP will consider the Company's responses at its meeting in September 2008, when an oral explanation hearing will be held if required. The Company continues to expect resolution of the remaining issues regarding the Marketing Authorization Application (MAA) for L-MTP-PE in the third quarter.

"The European review of L-MTP-PE continues to progress as expected as we work with the CHMP to address the additional data analyses as well as the remaining questions," said Timothy P. Walbert, president and chief executive officer, IDM Pharma. "We remain optimistic that we will have the CHMP opinion on L-MTP-PE in the third quarter this year."

With the CHMP opinion anticipated in the third quarter, IDM Pharma expects a decision from the European Commission in the fourth quarter of 2008. If approved for Marketing Authorization by the European Commission, L-MTP-PE will be the first treatment in more than 20 years approved for patients with osteosarcoma, a rare and often fatal bone tumor
'/>"/>

SOURCE IDM Pharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Isis Pharmaceuticals Conference Call Notice
2. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
3. Catalyst Pharmaceutical Partners, Inc. Begins Enrollment for U.S. Phase II Clinical Trial of CPP-109 in Patients with Methamphetamine Addiction
4. XTL Biopharmaceuticals Announces Completion of Patient Randomization Into the Bicifadine Phase 2b Clinical Trial for the Treatment of Diabetic Neuropathic Pain
5. MAP Pharmaceuticals Reports Positive Pharmacological Response Data for Migraine Product Candidate at the American Headache Society Annual Meeting
6. Phase III Data Show Vanda Pharmaceuticals Tasimelteon (VEC-162) Significantly Improves Sleep in Patients with Chronic Insomnia
7. Pharmasset Receives Notice of Allowance
8. Morria Biopharmaceuticals Plc Announces the Initiation of a Phase II Clinical Multi-dose Study of MRX-4 in Allergic Rhinitis
9. CB1400, Patented by Canopus BioPharma, Enters Phase II Clinical Trials for the Prevention of Mucositis in Patients With Cancer of the Head and Neck
10. Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting
11. Pharmaxis Concludes Special Protocol Assessment with FDA for Bronchitol Phase 3 Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Research and Markets ... the "Dental Consumables Market - Global Industry ... - 2018" report to their offering. ... ) Dental consumables are products which are ... impairments, for tooth restoration and in treatment of ...
(Date:1/15/2014)... , Jan. 15, 2014  Novation, the leading ... company, awarded several new IT value-added reseller (VAR) ... hospital organizations with IT goods and services at ... agreements, as well as value-added services such as ... New Novation agreements were awarded to ...
(Date:1/15/2014)... DUBLIN , January 15, 2014 ... that it has waived the Office of Fair Trading (OFT) ... the outstanding shares of ViroPharma Incorporated (NASDAQ: VPHM).   ... no longer conditional on OFT approval, and Shire expects to ... currently scheduled expiration time, subject to the satisfaction of all ...
Breaking Medicine Technology:Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3
... Systems U.S.A., Inc. is pleased to announce the FDA ... Wireless. This new wireless version of the company,s ... quality in a lightweight design for enhanced versatility and ... imaging applications. The FDR D-EVO Wireless will be featured ...
... presented from pooled analyses of the STELARA® (ustekinumab) psoriasis ... STELARA and rates of adverse events remained consistent and ... plaque psoriasis receiving up to four years of treatment. ... placebo-controlled Phase 3 trials across patient populations on three ...
Cached Medicine Technology:FUJIFILM's FDR D-EVO™ Wireless Now Available in the U.S. 2New Four Year STELARA® Data Show Consistent Safety Profile Over Time in Patients With Moderate to Severe Plaque Psoriasis 2New Four Year STELARA® Data Show Consistent Safety Profile Over Time in Patients With Moderate to Severe Plaque Psoriasis 3New Four Year STELARA® Data Show Consistent Safety Profile Over Time in Patients With Moderate to Severe Plaque Psoriasis 4New Four Year STELARA® Data Show Consistent Safety Profile Over Time in Patients With Moderate to Severe Plaque Psoriasis 5New Four Year STELARA® Data Show Consistent Safety Profile Over Time in Patients With Moderate to Severe Plaque Psoriasis 6New Four Year STELARA® Data Show Consistent Safety Profile Over Time in Patients With Moderate to Severe Plaque Psoriasis 7New Four Year STELARA® Data Show Consistent Safety Profile Over Time in Patients With Moderate to Severe Plaque Psoriasis 8New Four Year STELARA® Data Show Consistent Safety Profile Over Time in Patients With Moderate to Severe Plaque Psoriasis 9New Four Year STELARA® Data Show Consistent Safety Profile Over Time in Patients With Moderate to Severe Plaque Psoriasis 10New Four Year STELARA® Data Show Consistent Safety Profile Over Time in Patients With Moderate to Severe Plaque Psoriasis 11
(Date:4/14/2014)... treat children with uncomplicated acute appendicitis is a reasonable ... fewer missed school days, according to a pilot study. ... Hospital and published online April 12 in the ... the first prospective study on nonoperative management of acute ... , Researchers enrolled 77 patients age 7 to 17 ...
(Date:4/14/2014)... 2014, Perth, Australia. Drug discovery company Proteomics International ... of a companion diagnostic (CDx) test with the ... The research team authenticated the panel of biomarkers ... samples. Seven biomarkers were validated at high stringency ... The mass spectrometry data was then cross-validated using ...
(Date:4/14/2014)... 2014) When it comes to the cost and ... Patients get the best care when they are treated ... extensive experience in their current job, according to a ... and Columbia Business School. The study was published in ... Applied Economics . , The review of more ...
(Date:4/13/2014)... STANFORD, Calif. A low-cost empowerment program for ... and sexual harassment of these girls, who live ... and are frequently attacked, a large new study ... Stanford University School of Medicine, Lucile Packard Children,s ... No Worldwide, validated the program,s effectiveness in combating ...
(Date:4/11/2014)... the processes that control brain cell production could pave ... brain-related disorders. , Scientists have gained new understanding of ... how and when nerve and brain cells are formed ... and keeps it healthy. Their findings could help explain ... which is a fundamental characteristic of many diseases including ...
Breaking Medicine News(10 mins):Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 2Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 3Health News:Longer nurse tenure on hospital units leads to higher quality care 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 3Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 4
... their effort to ensure,this generation of veterans is ... partnered with St. Johns, University School,of Risk Management, ... (IICF) on a three-day "Warriors to Work" Insurance,Industry ... wounded,warriors, most of whom were from the New ...
... is the best available option for people with hemochromatosis ... is often dismissed as a primitive form of medicine, ... of bad humors by draining the life-sustaining fluid. , ... is still the preferred means of treatment. , Hemochromatosis ...
... quality of care, communication and productivity,to new levels, while improving ... ... disciplines of care, PITTSBURGH, Aug. 25 Vocollect Healthcare ... retirement,community located in Wyomissing, Pennsylvania, will deploy AccuNurse(R),voice- assisted care ...
... Fitness tops competition on Inc. 5000 list ... rakes in revenue and new members, DOVER, N.H., ... for its "Judgment Free" atmosphere and friendly prices, earned,the ... 2008 list of,the 5,000 fastest-growing private businesses in the ...
... be racing faster this fall for every medical student in ... student and resident must pass will be delivered in a ... a skill that some say has become an Achilles heel ... doctors and residents out there taking this test know they ...
... and supplies to the EMS market, announced today the release of ... design first introduced to the EMS community in 1999. , ... ... [Hartwell Medical], a leading supplier of [emergency medical equipment] and ...
Cached Medicine News:Health News:Wounded Warrior Project (WWP), St. John's University, and Insurance Industry Charitable Foundation Partner to Assist Wounded Warriors 2Health News:For Rare Blood Disorder, Pumping Iron Is the Cure 2Health News:For Rare Blood Disorder, Pumping Iron Is the Cure 3Health News:The Highlands at Wyomissing Invests in Voice-Assisted Care to Take Excellence in Retirement Living to New Levels 2Health News:The Highlands at Wyomissing Invests in Voice-Assisted Care to Take Excellence in Retirement Living to New Levels 3Health News:N.H.-Based Health Club Operator Sets The Industry's Pace 2Health News:Listen up! 2Health News:Hartwell Medical Announces Release of CombiCarrierII Scoop Backboard to EMS Market 2Health News:Hartwell Medical Announces Release of CombiCarrierII Scoop Backboard to EMS Market 3
... Stratasis TF is a minimally ... treat stress urinary incontinence resulting from ... sphincter deficiency. The Stratasis TF Kit ... antegrade or retrograde placement. Supplied ...
... Used to dilate the ... medium to assess possible submucosal ... a topical anesthetic in the ... passage by, or dislodgment of ...
Used for drainage and retrograde pyelogram. Supplied sterile in peel-open packages. Intended for one-time use....
Used for drainage and navigation of a tortuous ureter. The tapered tip eases placement as there are no edges to interfere with the ureteral orifice. Supplied sterile in peel-open packages. Intended f...
Medicine Products: